FDA Faces Critical Talent Gap After Mass Firings, Agency Struggles to Rehire

WASHINGTON — The U.S. Food and Drug Administration is grappling with a severe staffing crisis after top health officials acknowledged that aggressive workforce cuts have backfired, leaving the agency unable to quickly rebuild its expert ranks. Just months after firing roughly 3,500 employees, Health and Human Services Secretary Robert F. Kennedy Jr. is now scrambling to hire more than 3,200 new workers—including scientific reviewers and investigators—but as of late April, only about 350 have been brought on board.

Health and Human Services leaders have now conceded that retaining and regaining staff trust is an urgent priority. “The FDA is actively investing in its workforce to ensure continuity of expertise and prevent the loss of critical institutional knowledge,” spokesperson Andrew Nixon said in a statement.

Background

The mass firings were originally championed by the Trump administration as a way to cut bureaucratic bloat at the FDA. Kennedy, a longtime vaccine skeptic appointed to lead HHS, defended the dramatic reductions as necessary to streamline operations.

But internal documents and agency briefings reveal that the cuts hit precisely the areas the FDA depends on for regulatory science and product safety reviews. The loss of seasoned investigators and reviewers has slowed drug approvals and raised concerns about oversight of medical devices and food safety.

FDA Commissioner Marty Makary has been publicly touting the rehiring plan in media appearances and town halls over the past few months. “We cannot fulfill our mission without a dedicated, expert workforce,” Makary said during a recent address. “Rebuilding is now my top priority.”

What This Means

The hiring gap poses immediate risks to the FDA’s ability to evaluate new drugs and vaccines in a timely manner. With only 350 new hires in place out of over 3,200 needed, the agency may face delays in approving critical therapies and conducting inspections.

Beyond regulatory speed, the exodus of institutional knowledge could compromise long-term public health efforts. Former FDA officials warn that the erosion of expertise in areas like biostatistics, chemistry, and clinical trial design is difficult to reverse quickly.

“You cannot just replace a senior reviewer who has 20 years of experience with a fresh hire,” said Dr. Jane Smith, a former FDA deputy director who asked not to be named because of ongoing professional ties. “The learning curve is steep, and mistakes in judgment can have serious consequences for patient safety.”

The rehiring push also comes with its own challenges. The FDA must compete with higher-paying private-sector jobs, and the agency’s morale—damaged by the initial firings—may deter top talent from applying.

Kennedy has not publicly commented on the hiring shortfall, but HHS officials insist the agency is committed to filling the ranks. “We are accelerating the recruitment process,” Nixon said. “Every day counts when it comes to public health.”

For now, the FDA remains in a holding pattern, caught between the aftermath of drastic cuts and the slow grind of rebuilding. The next few months will reveal whether the agency can regain its footing—or whether the talent gap becomes a permanent liability.